You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

IMITREX STATDOSE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Imitrex Statdose patents expire, and what generic alternatives are available?

Imitrex Statdose is a drug marketed by Glaxosmithkline and is included in one NDA.

The generic ingredient in IMITREX STATDOSE is sumatriptan succinate. There are twenty-four drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the sumatriptan succinate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Imitrex Statdose

A generic version of IMITREX STATDOSE was approved as sumatriptan succinate by WEST-WARD PHARMS INT on February 6th, 2009.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for IMITREX STATDOSE?
  • What are the global sales for IMITREX STATDOSE?
  • What is Average Wholesale Price for IMITREX STATDOSE?
Drug patent expirations by year for IMITREX STATDOSE
Drug Prices for IMITREX STATDOSE

See drug prices for IMITREX STATDOSE

Recent Clinical Trials for IMITREX STATDOSE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
GlaxoSmithKlinePhase 1
Diamond Headache ClinicPhase 4
GlaxoSmithKlinePhase 4

See all IMITREX STATDOSE clinical trials

US Patents and Regulatory Information for IMITREX STATDOSE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline IMITREX STATDOSE sumatriptan succinate INJECTABLE;SUBCUTANEOUS 020080-002 Feb 1, 2006 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Glaxosmithkline IMITREX STATDOSE sumatriptan succinate INJECTABLE;SUBCUTANEOUS 020080-003 Dec 23, 1996 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for IMITREX STATDOSE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline IMITREX STATDOSE sumatriptan succinate INJECTABLE;SUBCUTANEOUS 020080-002 Feb 1, 2006 ⤷  Sign Up ⤷  Sign Up
Glaxosmithkline IMITREX STATDOSE sumatriptan succinate INJECTABLE;SUBCUTANEOUS 020080-003 Dec 23, 1996 ⤷  Sign Up ⤷  Sign Up
Glaxosmithkline IMITREX STATDOSE sumatriptan succinate INJECTABLE;SUBCUTANEOUS 020080-003 Dec 23, 1996 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.